Related references
Note: Only part of the references are listed.Clinical development of an anti-GPC-1 antibody for the treatment of cancer
Saikat Ghosh et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2022)
Ultrasound-Responsive Nrf2-Targeting siRNA-Loaded Nanobubbles for Enhancing the Treatment of Melanoma
Monica Argenziano et al.
PHARMACEUTICS (2022)
Chitosan-Shelled Nanobubbles Irreversibly Encapsulate Morpholino Conjugate Antisense Oligonucleotides and Are Ineffective for Phosphorodiamidate Morpholino-Mediated Gene Silencing ofDUX4
Maria Sofia Falzarano et al.
NUCLEIC ACID THERAPEUTICS (2021)
pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer
Priyanka Ray et al.
MOLECULAR PHARMACEUTICS (2021)
Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology
Cedric Leroux et al.
CANCERS (2021)
Advances in Pancreatic Ductal Adenocarcinoma Treatment
Eric M. Anderson et al.
CANCERS (2021)
siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model
Jae Yun Jung et al.
CELLS (2021)
Chitosan Nanoparticles at the Biological Interface: Implications for Drug Delivery
Noorjahan Aibani et al.
PHARMACEUTICS (2021)
Preparation of multifunctional nanobubbles and their application in bimodal imaging and targeted combination therapy of early pancreatic cancer
Hengli Yang et al.
SCIENTIFIC REPORTS (2021)
Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors
Jun Ushio et al.
DIAGNOSTICS (2021)
Immunotherapy in Pancreatic Adenocarcinoma: Beyond Copy/Paste
Robert Hester et al.
CLINICAL CANCER RESEARCH (2021)
Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
Christopher Montemagno et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Pancreatic Cancer: A Review
Wungki Park et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Evaluation of the In Vitro Cytotoxic Activity of Ursolic Acid PLGA Nanoparticles against Pancreatic Ductal Adenocarcinoma Cell Lines
Adam Markowski et al.
MATERIALS (2021)
A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma
Eri Munekage et al.
NEOPLASIA (2021)
The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy
Daniel R. Principe et al.
FRONTIERS IN ONCOLOGY (2021)
Developing Actively Targeted Nanoparticles to Fight Cancer: Focus on Italian Research
Monica Argenziano et al.
PHARMACEUTICS (2021)
Hybridoma technology; advancements, clinical significance, and future aspects
Sanchita Mitra et al.
JOURNAL OF GENETIC ENGINEERING AND BIOTECHNOLOGY (2021)
Anti-GPC1-modified mesoporous silica nanoparticles as nanocarriers for combination therapy and targeting of PANC-1 cells
Bianca Martins Estevao et al.
MATERIALS ADVANCES (2021)
The Current Landscape of Antibody-based Therapies in Solid Malignancies
Ashu Shah et al.
THERANOSTICS (2021)
Antibody-Drug Conjugates: A Comprehensive Review
Puregmaa Khongorzul et al.
MOLECULAR CANCER RESEARCH (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Chitosan Derivatives and Their Application in Biomedicine
Wenqian Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
Panagiotis Sarantis et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2020)
Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer
Takahiko Nishigaki et al.
BRITISH JOURNAL OF CANCER (2020)
AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review
Harry R. Aslanian et al.
GASTROENTEROLOGY (2020)
Carcinogenesis of Pancreatic Ductal Adenocarcinoma
Peter Storz et al.
GASTROENTEROLOGY (2020)
GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab
Daiki Kato et al.
ELIFE (2020)
Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines
Lukas M. Braun et al.
CELLS (2020)
From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma
Christopher Montemagno et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
CAR-T design: Elements and their synergistic function
Jayapriya Jayaraman et al.
EBIOMEDICINE (2020)
Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors
Matthew I. Confeld et al.
MOLECULAR PHARMACEUTICS (2020)
Cluster of differentiation 19 chimeric antigen receptor T-cell therapy in pediatric acute lymphoblastic leukemia
Zexin Fu et al.
ONCOLOGY LETTERS (2020)
Immunotherapy in hematologic malignancies
R. R. Kansara et al.
CURRENT ONCOLOGY (2020)
Micro/nano-bubble-assisted ultrasound to enhance the EPR effect and potential theranostic applications
Lei Duan et al.
THERANOSTICS (2020)
Histone methyltransferase G9a inhibitor-loaded redox-responsive nanoparticles for pancreatic ductal adenocarcinoma therapy
Jie-Qin Wang et al.
NANOSCALE (2020)
Glypican-3 expression in malignant small round cell tumors
Yuichi Shibui et al.
ONCOLOGY LETTERS (2019)
Novel immunotherapeutic approaches for hepatocellular carcinoma treatment
Davide Busato et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
The Hippo Signaling Pathway in Pancreatic Cancer
Daniel Ansari et al.
ANTICANCER RESEARCH (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
Michael Orth et al.
RADIATION ONCOLOGY (2019)
The Role of Glypican-3 in Regulating Wnt, YAP, and Hedgehog in Liver Cancer
Aarti Kolluri et al.
FRONTIERS IN ONCOLOGY (2019)
Nanobubble Liposome Complexes for Diagnostic Imaging and Ultrasound-Triggered Drug Delivery in Cancers: A Theranostic Approach
Ameya Prabhakar et al.
ACS OMEGA (2019)
Synthesis, Bioapplications, and Toxicity Evaluation of Chitosan-Based Nanoparticles
Balsam R. Rizeq et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Familial Pancreatic Ductal Adenocarcinoma
Kelly E. Diaz et al.
AMERICAN JOURNAL OF PATHOLOGY (2019)
Teaching an old dog new tricks: next-generation CAR T cells
Nicholas Tokarew et al.
BRITISH JOURNAL OF CANCER (2019)
Biocompatible Chitosan Nanobubbles for Ultrasound-Mediated Targeted Delivery of Doxorubicin
Xiaoying Zhou et al.
NANOSCALE RESEARCH LETTERS (2019)
The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview
Francisco Quinonero et al.
CANCER BIOLOGY & MEDICINE (2019)
Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment
Fubo Zhou et al.
MEDICINAL RESEARCH REVIEWS (2018)
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab- Paclitaxel/Gemcitabine Versus Nab- Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
Sunil R. Hingorani et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma
Min Yu et al.
MOLECULAR THERAPY (2018)
Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden
Adam E. Frampton et al.
Oncotarget (2018)
Folate-conjugated nanobubbles selectively target and kill cancer cells via ultrasound-triggered intracellular explosion
Shuxin Shen et al.
BIOMATERIALS (2018)
Targeted Therapies for Pancreatic Cancer and Hurdles Ahead
Minela Aslan et al.
ANTICANCER RESEARCH (2018)
Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer
Wenli Qiu et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
Andrew McGuigan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma
Cong-ya Zhou et al.
CANCER MEDICINE (2018)
Combining doxorubicin-nanobubbles and shockwaves for anaplastic thyroid cancer treatment: preclinical study in a xenograft mouse model
Francesca Marano et al.
ENDOCRINE-RELATED CANCER (2017)
Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma
Nan Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
α3 Chains of type V collagen regulate breast tumour growth via glypican-1
Guorui Huang et al.
NATURE COMMUNICATIONS (2017)
EVI1 modulates oncogenic role of GPC1 in pancreatic carcinogenesis
Mariko Tanaka et al.
ONCOTARGET (2017)
Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma
Emi Harada et al.
ONCOTARGET (2017)
Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma
Haizhen Lu et al.
CANCER MEDICINE (2017)
An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery
Munawar A. Mohammed et al.
PHARMACEUTICS (2017)
Cancer nanomedicine: a review of recent success in drug delivery
Stephanie Tran et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2017)
Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells
Elvira Pelosi et al.
BIOMEDICINES (2017)
Serum glypican 4 level in obese children and its relation to degree of obesity
Chutima Leelalertlauw et al.
CLINICAL ENDOCRINOLOGY (2017)
Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma
Hisashi Hara et al.
BRITISH JOURNAL OF CANCER (2016)
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy
Andre Goy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+B-cell Non-Hodgkin Lymphoma
Michinori Ogura et al.
CLINICAL CANCER RESEARCH (2016)
Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma
Christopher C. DuFort et al.
GASTROENTEROLOGY (2016)
A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns
Faiyaz Notta et al.
NATURE (2016)
Doxorubicin-Loaded Nanobubbles Combined with Extracorporeal Shock Waves: Basis for a New Drug Delivery Tool in Anaplastic Thyroid Cancer
Francesca Marano et al.
THYROID (2016)
Glypican-1 as a Biomarker for Prostate Cancer: Isolation and Characterization
Quach Truong et al.
JOURNAL OF CANCER (2016)
Pancreatic cancer
Jorg Kleeff et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Reducing Tumour Hypoxia via Oral Administration of Oxygen Nanobubbles
Joshua Owen et al.
PLOS ONE (2016)
Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study
Fiona M. Walter et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer
Xiao Zhao et al.
BIOMATERIALS (2015)
Structural Aspects of N-Glycosylations and the C-terminal Region in Human Glypican-1.
Wael Awad et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
Sonia A. Melo et al.
NATURE (2015)
Diagnostic and prognostic significance of glypican 5 and glypican 6 gene expression levels in gastric adenocarcinoma
Melike Dinccelik-Aslan et al.
MOLECULAR AND CLINICAL ONCOLOGY (2015)
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Tianmeng Sun et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
Huiping Gao et al.
CLINICAL CANCER RESEARCH (2014)
Heparan Sulfate Proteoglycans and Human Breast Cancer Epithelial Cell Tumorigenicity
Rachel K. Okolicsanyi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2014)
Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer
Linjuan Zeng et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2014)
Pathology of pancreatic ductal adenocarcinoma: Facts, challenges and future developments
Irene Esposito et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
2564 resected periampullary adenocarcinomas at a single institution: trends over three decades
Jin He et al.
HPB (2014)
Potential and problems in ultrasound-responsive drug delivery systems
Ying-Zheng Zhao et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2013)
Association of Glypican-4 With Body Fat Distribution, Insulin Resistance, and Nonalcoholic Fatty Liver Disease
H. J. Yoo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Sonic Hedgehog Regulates Its Own Receptor on Postcrossing Commissural Axons in a Glypican1-Dependent Manner
Nicole H. Wilson et al.
NEURON (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
New chitosan nanobubbles for ultrasound-mediated gene delivery: preparation and in vitro characterization
Roberta Cavalli et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2012)
Crystal Structure of N-Glycosylated Human Glypican-1 Core Protein STRUCTURE OF TWO LOOPS EVOLUTIONARILY CONSERVED IN VERTEBRATE GLYPICAN-1
Gabriel Svensson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2011)
Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling
Fuchuan Li et al.
JOURNAL OF CELL BIOLOGY (2011)
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Common variation in GPC5 is associated with acquired nephrotic syndrome
Koji Okamoto et al.
NATURE GENETICS (2011)
Glypican-1 controls brain size through regulation of fibroblast growth factor signaling in early neurogenesis
Yi-Huei Linda Jen et al.
NEURAL DEVELOPMENT (2009)
Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: A tissue microarray analysis of 4,387 tissue samples
Daniel Baumhoer et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface
Alexandra Traister et al.
BIOCHEMICAL JOURNAL (2008)
Involvement of glypican-1 autoprocessing in scrapie infection
Kajsa Lofgren et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2008)
Matrix metalloproteinase-9 associated with heparan sulphate chains of GPI-anchored cell surface proteoglycans mediates motility of murine colon adenocarcinoma cells
Yoshie Koyama et al.
JOURNAL OF BIOCHEMISTRY (2008)
Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells
Takurna Aikawa et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Frank Alexis et al.
MOLECULAR PHARMACEUTICS (2008)
Nanoparticle therapeutics: an emerging treatment modality for cancer
Mark E. Davis et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Glypican-3 expression in primary and recurrent ovarian carcinomas
Sylvia Stadlmann et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2007)
Role for amplification and expression of Glypican-5 in rhabdomyosarcoma
Daniel Williamson et al.
CANCER RESEARCH (2007)
Defective nitric oxide-dependent, deaminative cleavage of glypican-1 heparan sulfate in Niemann-Pick C1 fibroblasts
Katrin Mani et al.
GLYCOBIOLOGY (2006)
Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells
Gui Su et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Evidence for a role of developmental genes in the origin of obesity and body fat distribution
S Gesta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Heparan sulphate proteoglycans:: The sweet side of development
U Häcker et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
Glypican-1 as an Aβ binding HSPG in the human brain:: Its localization in DIG domains and possible roles in the pathogenesis of Alzheimer's disease
N Watanabe et al.
FASEB JOURNAL (2004)
Glypican-1 antisense transfection modulates TGF-β-dependent signaling in Colo-357 pancreatic cancer cells
JS Li et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Identification of glypican-3 as a novel tumor marker for melanoma
T Nakatsura et al.
CLINICAL CANCER RESEARCH (2004)
Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma
M Capurro et al.
GASTROENTEROLOGY (2003)
Developmental roles of the glypicans
B De Cat et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2001)
Glypicans in growth control and cancer
J Filmus
GLYCOBIOLOGY (2001)